2 active not recruiting, 2 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 2, Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Aggressive Lymphoma: new trials by email Literature Review of Aggressive Lymphoma trials Research Report on Aggressive Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma Mosunetuzumab - B Cell Lymphoma, Aggressive Lymphoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 9 | 2022-12-22 | 2026-10-13 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers NKX019 - Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Nkarta, Inc. | 150 | 2021-08-20 | 2026-04-20 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia TG-1801, Ublituximab - CLL, SLL | Phase 1 | Terminated | TG Therapeutics, Inc. | 21 | 2021-04-28 | 2024-07-31 |
| A Study Of The Selective PKC-β Inhibitor MS- 553 MS-553, acalabrutinib, venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 60 | 2018-05-25 | 2025-04-10 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Follicular (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma (3) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, B-Cell (2) · Leukemia, Lymphoid (2) · Lymphoma, B-Cell (2)
LFB-R603 (1) · Rituximab (1) · acalabrutinib (1) · obinutuzumab (1) · ublituximab (1) · venetoclax (1)
MingSight Pharmaceuticals, Inc (1) · Nkarta, Inc. (1) · TG Therapeutics, Inc. (1) · Washington University School of Medicine (1)
United States (4) · Australia (1)
Armin Ghobadi, M.D. (1) · David Shook, MD (1)